111 related articles for article (PubMed ID: 8052342)
1. Effect of miglitol (BAY m-1099) on fasting blood glucose in type 2 diabetes mellitus.
Sels JP; Kingma PJ; Wolffenbuttel BH; Menheere PP; Branolte JH; Nieuwenhuijzen Kruseman AC
Neth J Med; 1994 Jun; 44(6):198-201. PubMed ID: 8052342
[TBL] [Abstract][Full Text] [Related]
2. Smoothing effect of a new alpha-glucosidase inhibitor BAY m 1099 on blood glucose profiles of sulfonylurea-treated type II diabetic patients.
Arends J; Willms BH
Horm Metab Res; 1986 Nov; 18(11):761-4. PubMed ID: 3539737
[TBL] [Abstract][Full Text] [Related]
3. Effect of Miglitol (Bay m1099), a new alpha-glucosidase inhibitor, on glucose, insulin, C-peptide and GIP responses to an oral sucrose load in patients with post-prandial hypoglycaemic symptoms.
Renard E; Parer-Richard C; Richard JL; Jureidini S; Orsetti A; Mirouze J
Diabete Metab; 1991; 17(3):355-62. PubMed ID: 1884880
[TBL] [Abstract][Full Text] [Related]
4. A double-blind study on the efficacy and tolerance of a new alpha-glucosidase inhibitor in type-2 diabetics.
Katsilambros N; Philippides P; Toskas A; Protopapas J; Frangaki D; Marangos M; Siskoudis P; Anastasopoulou K; Xefteri H; Hillebrand I
Arzneimittelforschung; 1986 Jul; 36(7):1136-8. PubMed ID: 3533089
[TBL] [Abstract][Full Text] [Related]
5. [Alpha-glucosidase inhibitor for type 2 diabetic patients. Clinical study with miglitol].
Fehmann HC
MMW Fortschr Med; 2000 May; 142(21):55. PubMed ID: 10872296
[No Abstract] [Full Text] [Related]
6. Does suppression of postprandial blood glucose excursions by the alpha-glucosidase inhibitor miglitol improve insulin sensitivity in diet-treated type II diabetic patients?
Johnson AB; Taylor R
Diabetes Care; 1996 Jun; 19(6):559-63. PubMed ID: 8725851
[TBL] [Abstract][Full Text] [Related]
7. Miglitol for type 2 diabetes mellitus.
Med Lett Drugs Ther; 1999 May; 41(1053):49-50. PubMed ID: 10368700
[No Abstract] [Full Text] [Related]
8. Long-term effectiveness of a new alpha-glucosidase inhibitor (BAY m1099-miglitol) in insulin-treated type 2 diabetes mellitus.
Mitrakou A; Tountas N; Raptis AE; Bauer RJ; Schulz H; Raptis SA
Diabet Med; 1998 Aug; 15(8):657-60. PubMed ID: 9702468
[TBL] [Abstract][Full Text] [Related]
9. Effect of exenatide on 24-hour blood glucose profile compared with placebo in patients with type 2 diabetes: a randomized, double-blind, two-arm, parallel-group, placebo-controlled, 2-week study.
Schwartz SL; Ratner RE; Kim DD; Qu Y; Fechner LL; Lenox SM; Holcombe JH
Clin Ther; 2008 May; 30(5):858-67. PubMed ID: 18555933
[TBL] [Abstract][Full Text] [Related]
10. Dose-dependent efficacy of miglitol, an alpha-glucosidase inhibitor, in type 2 diabetic patients on diet alone: results of a 24-week double-blind placebo-controlled study.
Drent ML; Tollefsen AT; van Heusden FH; Hoenderdos EB; Jonker JJ; van der Veen EA
Diabetes Nutr Metab; 2002 Jun; 15(3):152-9. PubMed ID: 12173729
[TBL] [Abstract][Full Text] [Related]
11. The acute effects of glucosidase inhibition on post-meal glucose increments in insulin-dependent diabetics.
Wing J; Kalk WJ; Berzin M; Diamond TH; Griffiths RF; Smit AM; Osler CE
S Afr Med J; 1990 Mar; 77(6):286-8. PubMed ID: 2180090
[TBL] [Abstract][Full Text] [Related]
12. Miglitol combined with metformin improves glycaemic control in type 2 diabetes.
Van Gaal L; Maislos M; Schernthaner G; Rybka J; Segal P
Diabetes Obes Metab; 2001 Oct; 3(5):326-31. PubMed ID: 11703422
[TBL] [Abstract][Full Text] [Related]
13. Miglitol and hepatotoxicity in type 2 diabetes mellitus.
Carlson RF
Am Fam Physician; 2000 Jul; 62(2):315, 318. PubMed ID: 10929699
[No Abstract] [Full Text] [Related]
14. The efficacy and safety of miglitol therapy compared with glibenclamide in patients with NIDDM inadequately controlled by diet alone.
Segal P; Feig PU; Schernthaner G; Ratzmann KP; Rybka J; Petzinna D; Berlin C
Diabetes Care; 1997 May; 20(5):687-91. PubMed ID: 9135927
[TBL] [Abstract][Full Text] [Related]
15. Study of the effect of miglitol on the pharmacokinetics and pharmacodynamics of warfarin in healthy males.
Schall R; Müller FO; Hundt HK; Duursema L; Groenewoud G; Middle MV
Arzneimittelforschung; 1996 Jan; 46(1):41-6. PubMed ID: 8821516
[TBL] [Abstract][Full Text] [Related]
16. Effects of miglitol, an alpha-glucosidase inhibitor, on glycaemic status and histopathological changes in islets in non-obese, non-insulin-dependent diabetic Goto-Kakizaki rats.
Goda T; Suruga K; Komori A; Kuranuki S; Mochizuki K; Makita Y; Kumazawa T
Br J Nutr; 2007 Oct; 98(4):702-10. PubMed ID: 17537288
[TBL] [Abstract][Full Text] [Related]
17. Evaluation of the efficacy, safety and tolerability of miglitol in adult Indian patients with uncomplicated type 2 diabetes mellitus.
Singh KP; Periyandavar I; Rajadhyaksha GC; Jayaram S; Mishra AB; Kinagi S; Sharma A; Baliga VP
J Indian Med Assoc; 2007 Jun; 105(6):344, 346, 350. PubMed ID: 18232183
[TBL] [Abstract][Full Text] [Related]
18. Advantages of alpha-glucosidase inhibition as monotherapy in elderly type 2 diabetic patients.
Johnston PS; Lebovitz HE; Coniff RF; Simonson DC; Raskin P; Munera CL
J Clin Endocrinol Metab; 1998 May; 83(5):1515-22. PubMed ID: 9589648
[TBL] [Abstract][Full Text] [Related]
19. Design and evaluation of oral bioadhesive controlled release formulations of miglitol, intended for prolonged inhibition of intestinal alpha-glucosidases and enhancement of plasma glucagon like peptide-1 levels.
Deshpande MC; Venkateswarlu V; Babu RK; Trivedi RK
Int J Pharm; 2009 Oct; 380(1-2):16-24. PubMed ID: 19563873
[TBL] [Abstract][Full Text] [Related]
20. Effects of 8-wk alpha-glucosidase inhibition on metabolic control, C-peptide secretion, hepatic glucose output, and peripheral insulin sensitivity in poorly controlled type II diabetic patients.
Schnack C; Prager RJ; Winkler J; Klauser RM; Schneider BG; Schernthaner G
Diabetes Care; 1989 Sep; 12(8):537-43. PubMed ID: 2673693
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]